Little clinical data are available regarding re-establishing the effective inhibition of entecavir (ETV)-resistant mutants. In this retrospective study, we aimed to compare the efficacies of four treatment regimens as rescue therapy for those chronic hepatitis B (CHB) patients with ETV resistance.
Introduction
There are currently seven approved antivirals for chronic hepatitis B virus (HBV) (CHB) infection: two interferons and five nucleos(t)ide analogues (NAs). The NAs include lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (LDV) and tenofovir (TDF). The advantages of NA therapy include ease of administration (dosed orally) and general absence of clinically significant adverse effects. However, with the long duration of treatment and wide application, the challenge with NA therapy is drug resistance, and even ETV resistance is not uncommon in clinical practice. The emergence of drug-resistant viral strains is preceded with increased viral load, followed by elevated serum alanine aminotransferase (ALT) level, an indication for progression of liver disease [1, 2] . Therefore, the development of NA resistance remains a major concern in the treatment of chronic HBV infection.
Entecavir is a novel deoxyguanosine analogue, which exhibits potent inhibition of HBV replication in vitro, in animal models, and in chronically infected patients [3] [4] [5] [6] . However, many ETV-treated patients who had received their early antiviral treatment with LAM, which has a low genetic barrier to resistance, already carried the LAM-resistant HBV mutants. Since the ETV resistance barrier is lowered by the presence of the LAM-resistant HBV mutations, one of which is rtM204V/I, the rate of ETV resistance increases up to 51% after 5 years of ETV treatment in patients with LAM-resistant HBV [7, 8] .
To date, clinical data on the efficacy of the rescue therapy in patients infected with ETV-resistant HBV strains are limited. The various international guidelines differ in recommending rescue therapeutic regimens for these patients. For example, the American Association for the Study of Liver Diseases recommends replacing ETV with ADV or TDF monotherapy, whereas the European and Asian-Pacific guidelines recommend switching to or adding TDF to ETV [9] [10] [11] [12] . There is no a clear principle established for guiding the design of rescue therapy for HBV drug resistance.
To accumulate clinical evidence and to establish the needed principle for guiding the design of effective rescue therapy, we aimed to investigate and compare the efficacies of four rescue treatment regimens of TDF, ETV (0.5 mg) + ADV, ETV (1.0 mg) and TDF + ETV(0.5 mg) for CHB patients with entecavir resistance in this retrospective study. The aim was to determine whether a clear rule that can guide an effective rescue therapy could emerge from this study.
Patients and methods

Patients and study design
This single-centre, retrospective investigator-initiated cohort study enrolled 1217 patients who failed on prior NA therapies and accepted antiviral drug resistance mutation detection in Nanfang Hospital, Southern Medical University between September 2013 and September 2015. Of these, 98 patients were confirmed to have genotypic resistance to ETV (the presence of rtT184A/C/F/G/I/L/S, rtS202G or rtM250L/V, in addition to rtM204V/I) and 65 patients were included in final analysis ( Figure 1 ). Patients with decompensated liver disease (ascites, variceal bleeding or encephalopathy) or renal impairment (serum creatinine ≥1.5 mg dl À1 ) were excluded.
Other exclusion criteria were as follows: coinfection with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus; a history of alcohol or drug abuse within the preceding 2 years; documented or suspected hepatocellular carcinoma (HCC); prior organ transplantation; and pregnancy/lactation. The study was approved by the Ethical Committee of Nanfang Hospital, Southern Medical University (NFEC-2014-079). The experiments were carried out in accordance with the approved guidelines and 'informed' consent was obtained from all subjects. In designing possible rescue therapies, we included two different NAs of TDF and ADV, resulting in four rescue treatment groups:
Group 1 (n = 21): TDF monotherapy (300 mg); Group 2 (n = 19): a combination of ETV (0.5 mg) with ADV (10 mg); Group 3 (n = 11): double dose of ETV monotherapy at 1 mg; Group 4 (n = 14): TDF (300 mg) add-on to ETV (0.5 mg).
ADV monotherapy was not selected as a rescue therapy because of high incidence of drug resistance induced by the ADV monotherapy.
Serum assays
The serum HBV DNA level was measured using the Cobras Taqman HBV Kit (Roche Diagnostics, Indianapolis, IN, USA; lower limit of detection, 20 IU ml À1 ). HBeAg, anti-HBe and anti-HBc were detected using an Architect assay (Abbott Laboratories, Abbott Park, IL, USA). Aminotransferases were measured according to standard procedures locally at the time of sampling. Antiviral drug resistance mutations were determined by restriction fragment mass polymorphism (RFMP) analyses and direct sequencing of the reverse transcriptase region of the HBV polymerase gene (pol/RT). Sequencing was performed on PCR products amplified from patient sera using the standard protocol for the ABI 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
Efficacy endpoints and definitions
The primary endpoint of this study was that the serum HBV DNA (<20 IU ml À1 ) became PCR undetectable. The secondary endpoints included a reduction in serum HBV DNA vs. the baseline level, serum alanine aminotransferase (ALT) normalization (≤ 40 IU l À1 ) and/or HBeAg loss or seroconversion at week 48. Virologic breakthrough, which is usually associated with drug resistance, was defined as a ≥1 log 10 IU ml À1 increase in serum HBV DNA level from nadir in two consecutive samples 1 month apart while receiving treatment and after achieving an initial response in medically compliant patients on antiviral medication(s).
Statistical analysis
All statistical analyses were conducted using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). Continuous variables were expressed in mean ± standard deviation or median (minimal value, maximal value), as appropriate. A logarithmic transformation was applied to HBV-DNA and HBsAg levels. Qualitative differences between subgroups were analyzed using R × C χ 2 tests. One-way analysis of variance (ANOVA) and Kruskal-Wallis tests were adopted appropriately. A two-sided P-value of <0.05 was considered statistically significant. NCSS-PASS software was used to perform the power calculation.
Results
Baseline characteristics of patients
A total of 65 patients were included in this analysis. The mean age in groups 1-4 was 51 ± 11, 51 ± 12, 48 ± 10 and 49 ± 11, respectively. The majority of patients were male in all groups. A total of 18 cases (85.72%) in group 1 were HBeAg positive, 16 cases (84.21%) in group 2, 9 cases (81.82%) in group 3 and 12 cases (85.71%) in group 4. There were no significant differences among the four study groups in demographic and laboratory characteristics at baseline (Table 1 ). All patients had various combinations of resistance mutations to LAM and ETV (rtM204V/I, rtL180M, rtT184A/C/F/G/I/L/S, rtS202G and rtM250L/V; Table 1 ), but none had HBV mutations conferring resistance to ADV (i.e., rtA181V/T and/or rtN236T).
Virological response
Serum HBV DNA levels declined significantly in response to the rescue therapy in all groups. The median reduction in serum HBV DNA level from baseline to week 48 was À2.37 ± 1.07 log 10 IU ml À1 in the TDF group, À2.16 ± 0.81 log 10 IU ml À1 in the ETV (0.5 mg) + ADV group, À1.17 ± 1.23 log 10 IU ml À1 in the ETV (1.0 mg) group and À2.49 ± 1.10
Figure 1
Patient recruitment flowchart Four rescue therapies for CHB patients with ETV resistance Table 1 Baseline characteristics of study patients 21 (100) 19 (100) 11 (100) 14 (100) rtM204V/I + rtL180M + rtT184G log 10 IU ml À1 in the ETV (0.5 mg) + TDF group (F = 4.078, P = 0.011; Figure 2 ). The TDF group and ETV (0.5 mg) + TDF group achieved the highest undetectable HBV DNA rate (76.19% and 78.57%), while the ETV (1.0 mg) and the ETV (0.5 mg) + ADV groups had 63.16% and 18.18%, respectively (Table 2) .
Biochemical and serological responses
No significant differences were detected in the percentage of patients with normal ALT levels at week 48 among the four groups (80.95%, 73.68%, 45.45% and 85.71%, respectively; χ 2 = 5.713, P = 0.126). However, significantly higher percentages of patients who normalized the ALT from the elevated levels at baseline were detected in TDF, ETV + TDF and ETV + ADV groups comparing the 1 mg ETV group at week 48 (71.43%, 61.54% and 77.78% vs. 14.29% respectively; χ 2 = 8.362, P = 0.039; Table 2 ).
The proportion of HBeAg-positive patients who achieved HBeAg seroclearance at week 48 was low, and no significant differences were observed among the four groups (11.11%, 6.25%, 0 and 16.67%, respectively; χ 2 = 2.657, P = 0.448; Table 2 ). No significant betweengroup differences emerged in the proportion of patients who achieved HBeAg seroconversion at week 48 (5.56%, 6.25%, 0, 8.33%, respectively; χ 2 = 1.196, P = 0.754; Table 2 ). None of the treated patients achieved HBsAg loss or seroconversion.
Virological breakthrough
Two patients in the ETV (1.0 mg) group experienced virological breakthrough at week 48, which was associated with non-compliance to the treatment regimens. At the time of the breakthrough, only early substitutions at baseline, but no additional amino acid substitution, was detected. None of these patients developed a biochemical breakthrough.
Safety
No serious adverse events were judged to be related to the rescue therapy. In particular, no deterioration of renal function, leading to discontinuation of the therapy or dose reduction, occurred.
Figure 2
Changes in HBV viral loads during the rescue therapy. The changes in serum HBV DNA levels from baseline during the treatment period, plotted as mean log 10 change from baseline values, are shown for each group. HBV, hepatitis B virus; ADV, adefovir dipivoxil (10 mg day À1 ); ETV, entecavir; LAM, lamivudine (100 mg day À1 ); TDF, tenofovir disoproxil fumarate (300 mg day À1 ) Four rescue therapies for CHB patients with ETV resistance
Power calculation
We used NCSS-PASS software to perform the power calculation. In a one-way ANOVA study, sample sizes of 21, 19, 11 and 14 are obtained from the four groups whose means are to be compared. The total sample of 65 subjects achieves 97% power to detect differences among the means vs. the alternative of equal means using an F-test with a 0.05 significance level.
Discussion
It has been a significant challenge to retreat CHB patients with drug resistance, especially the emergent resistant mutants from the ETV treatment. In this study, we explored the efficacies of four rescue treatment regimens for patients with ETV resistance. We found that: ETV resistant mutants can be effectively inhibited with monotherapy of a different NA as long as the NA, like TDF selected in this study for the rescue therapy, is as potent as ETV; resistant mutants can also be inhibited by addition of a weak NA like ADV while keeping ETV in the regimens; a combination of ETV with TDF does not seem to result in significantly superior efficacy compared to TDF monotherapy though it doubles the expense; and a double dose of ETV largely fails to overcome the ETV drug mutant resistance. A fundamental mechanism for the emergence of NA drug resistance is the introduction of mutated nucleotide in the HBV pol gene coding the RT domain, which leads to changes in both amino acids and conformations of RT that the small molecule inhibitors can no longer bind and inhibit efficiently [4, 13, 14] . It is appreciable that TDF can potently inhibit the ETV drug resistant mutants because the inhibition of wildtype HBV replication by TDF is equivalent to ETV if not stronger, and they differ in chemical structure and target different pockets in the RT domain [15] [16] [17] . It appears that these drug-resistant mutants became less susceptible to ETV, but remained sensitive to TDF, an indication that these mutations do not significantly adversely affect the TDF binding in the specific pocket of the RT domain.
An interesting finding in this study is that an ADV add-on rescue therapy was almost as effective as TDF monotherapy. In 12 of 19 patients (63.16%), serum HBV DNA levels declined to undetectable levels. Moreover, 8 of 13 patients (61.54%) achieved ALT normalization and 1 of 16 patients (6.25%) had HBeAg cleared and converted. Though some studies have suggested ADV, even in combination with ETV, has limited efficacy in treating ETV-resistant patients, with high rates of virological breakthrough and additional emergence of ADV resistant mutations, other in vitro studies have demonstrated that the ETV-resistant HBV mutants remain sensitive to ADV. In line with our findings, we suggest that ADV could be a treatment option for patients with ETVresistant HBV [18] [19] [20] .
ADV is a second-generation NA and better than LAM in terms of efficacy, but it is still prone to inducing higher drug-resistant mutants even in a relatively short treatment course when used as monotherapy. Even though ETV and TDF represent the first line of choice for treating chronic HBV infection, ADV can still be valuable in clinic. It has been reported that no drug resistance was detected in CHB patients treated with a combination of LAM, which is known for the highest frequency of drug resistance, with ADV for 192 weeks while the treatment regimens produced the sustained response in 68% of the treated patients compared to 31% with ADV alone [21] . Such results suggest that a synergy of LAM and ADV not only increases the potency of inhibition, but also significantly minimizes the emergence of drug resistance despite the high frequency of drug mutants if either is used individually. It was the same case in this study: when the ADV was combined with ETV, the efficiency of inhibiting ETV mutants was effectively restored. A likely mechanism is that ADV binding can compensate the reduced ETV inhibition with ETV binding when more than one pocket in the mutated RT domain is bound by both ETV and ADV. Thus, the more bindings to the pockets by different inhibitors, the higher the inhibition efficiency. The likelihood for appearance of drug resistance phenotype is inversely related to inhibition efficiency. The stronger the inhibition, the less likely any drug resistance. Our results imply that ETV drug resistance can be effectively overcome by ADV add-on or possibly by a combination of ADV with other NAs for rescue therapy, a much less expensive option.
Our study also suggests little benefit is gained by TDF addon to ETV and the treatment responses to TDF and ETV combination therapy was likely mediated by TDF alone. In our view, the TDF add-on was not cost-effective considering how expensive these two drugs are, both of which belong to the new generation of NAs.
The regimen with doubling ETV dose, as expected, worked poorly against the ETV mutants, suggesting that an increase in the number of ETV molecules alone cannot effectively address the issue of drug resistance, which does not derive from an insufficient concentration of ETV molecules in the cells, but is a result of the altered pocket in the RT domain, in which the ETV binding no longer fits. To effectively overcome the drug resistance, a different NA inhibitor that can bind to a different pocket in the RT domain is required in the rescue therapy.
To date, entecavir resistance is relatively rare and only few studies are available on this important topic. Our cohort, though the absolute number of the included patients is small, represents a relatively large number of cases in the context of ETV resistance. The experience and findings of this study, which compares four different rescue regimens, offer a clue to formulating a standard management for ETV resistance.
There are some limitations to the study. First, this study was retrospectively designed, though objective endpoints (virological, serological and biochemical) were elaborately recorded. Second, the sample size was relatively small, which is associated with the relatively low resistant rate of ETV and the limitation of a single-centre study. Third, 33 ETV-resistant patients were excluded form the final analysis, which reduced the power of statistical analysis. Among the excluded 33 patients, four were coinfected with HCV, one was coninfected with HIV, and the remaining 28 patients did not have the complete follow-up data including HBV DNA. Fourth, we were unable to make multiple comparisons according to the test of homogeneity of variance. The positive P-value when comparing the treatment arms was completely dependent on the high failure rates in the group with continued entecavir as a monotherapy.
In conclusion, our findings suggest that: a double dose of ETV is not an effective solution to ETV resistance; and a different NA inhibitor is required for overcoming ETV resistance, either using a potent NA like TDF as monotherapy or adding a less potent one like ADV as combination therapy. However, because of the small sample size and retrospective design of this study, our findings and conclusions need to be verified in new prospective randomized long-term studies.
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